12.07.2018 – 18:16

BB Biotech AG

DGAP-Adhoc: BB Biotech AG reports preliminary results for 1H 2018

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results
BB Biotech AG reports preliminary results for 1H 2018

12-Jul-2018 / 18:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Media Release, July 12, 2018
 
BB Biotech AG reports preliminary results for 1H 2018
 
In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN
CH0038389992) is releasing the following information about its results for the
first half year of 2018.
 
Based on preliminary unaudited consolidated results, BB Biotech closed the first
half year of 2018 with a loss of around CHF 70 mn (CHF 478.4 mn profit in the
corresponding period of the previous year). As an investment company, the result
reflects the performance of the stocks it holds in its investment portfolio.
 
BB Biotech's share price increased 8.4% in CHF and 8.2% in EUR during the
corresponding period.
 
 
The interim report as of June 30, 2018 will be published on July 20, 2018.
 
 
 
 
For further information:
 
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel.
+41 44 267 67 00
Dr. Silvia Schanz,ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio,mga@bellevue.ch
Claude Mikkelsen,cmi@bellevue.ch
 
Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel.
+41 44 267 67 07
Tanja Chicherio,tch@bellevue.ch
 
www.bbbiotech.com
 
 
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector. BB Biotech is listed in
Switzerland, Germany and Italy. Its investments are focused on listed companies
that are developing and commercializing novel medical treatments and cures. BB
Biotech's investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has many
years of experience in industry and science.------------------------------------
12-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
--------------------------------------------------------------------------------

Language: English

Company:  BB BIOTECH AG

          Schwertstrasse 6

          8200 Schaffhausen

          Switzerland

Phone:    +41 52 624 08 45

E-mail:    info@bbbiotech.com

Internet: www.bbbiotech.ch

ISIN:     CH0038389992

WKN:      A0NFN3

Listed:   Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial
Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX



 

End of Announcement DGAP News Service

--------------------------------------------------------------------------------

703867  12-Jul-2018 CET/CEST